STOCK Tg(tetO-Fgfr2b/Igh)1.3Jaw/J

Stock number: 025672
Research areas: Research Tools

Description

These transgenic mice carry the FGFR-HFc inhibitor of FGF signaling, regulated by a tetracycline operator (tetO)/minimal cytomegalovirus (CMV) promoter. When mated to a mutant strain expressing tetracycline-controlled transactivator protein (tTA), expression of the dominant-negative FGFR-HFc protein may be regulated with the tetracycline analog doxycycline (dox) in the double mutant offspring. These mice may be useful for studying FGF signaling in development of the embryo and in the adult mouse.

Detailed description

The Fgfr2b gene encodes for a tyrosine protein kinase, fibroblast growth factor receptor, that is required for embryonic patterning, lung development, osteoblast differentiation, and skin development. The soluble chimeric dominant-negative FGFR-HFc construct consists of the extracellular domain of the mouse Fgfr2b, fibroblast growth factor receptor 2, gene and the heavy chain hinge and Fc domain of the mouse immunoglobulin (Igh, immunoglobulin heavy chain complex). Expression of the FGFR-HFc construct is regulated by a tetracycline operator (tetO)/minimal cytomegalovirus (CMV) promoter, in this transgenic strain. When mated to a mutant strain expressing tetracycline-controlled transactivator protein (tTA), expression of the mutant Fgfr2 may be regulated with tetracycline or its analog doxycycline (dox) in the double mutant offspring. Mice hemizygous for the transgene are viable and fertile. The Donating Investigator has not attempted to make the strain homozygous.

Development

A transgenic vector containing the soluble chimeric dominant-negative FGFR-HFc construct, which consists of the extracellular domain of the mouse Fgfr2b, fibroblast growth factor receptor 2, gene and the heavy chain hinge and Fc domain of the mouse immunoglobulin (Igh, immunoglobulin heavy chain complex), under control of a tetracycline operator (tetO)/minimal cytomegalovirus (CMV) promoter, was utilized in the construction of this transgenic strain. The construct was microinjected into FVB/N fertilized oocytes. Founder line 1.3 was subsequently established and maintained on the FVB/N background (see SNP note below). Upon arrival at The Jackson Laboratory, the mice were crossed to FVB/NJ (Stock No. 001800) at least once to establish the colony.

A 32 SNP (single nucleotide polymorphism) panel analysis, with 27 markers covering all 19 chromosomes and the X chromosome, as well as 5 markers that distinguish between the C57BL/6J and C57BL/6N substrains, was performed on the rederived living colony at The Jackson Laboratory Repository. Five of the 27 markers throughout the genome were segregating, suggesting an unknown contributing background.

Allele

Symbol: Tg(tetO-Fgfr2b/Igh)1.3Jaw
Name: transgene insertion 1.3, Jeffrey A Whitsett
MGI accession ID: MGI:5582625
Generation method: Transgenic
Attributes: Inducible; Inserted expressed sequence
Marker symbol: Tg(tetO-Fgfr2b/Igh)1.3Jaw
Marker name: transgene insertion 1.3, Jeffrey A Whitsett
Chromosome: UN
Strain of origin: FVB/N
Expressed genes: Fgfr2,fibroblast growth factor receptor 2,mouse, laboratory; Igh,immunoglobulin heavy chain complex,mouse, laboratory
Molecular note: A transgenic vector containing the soluble chimeric dominant-negative FGFR-HFc construct, which consists of the extracellular domain of the mouse Fgfr2b gene and the heavy chain hinge and Fc domain of the mouse immunoglobulin, under control of a tetracycline operator (tetO)₇/minimal cytomegalovirus (CMV) promoter, was utilized in the construction of this transgenic strain. Founder lines 1.3 and 5.9 were generated, it is not known how they compare to each other.